| Novel DBS Device in Parkinson's Disease (NCT07213999) | University of Minnesota | 2022-07-01 |
| Moving Yourself in Space and Time: MYSTIC (NCT07697664) | Emory University | 2022-03-25 |
| Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease (NCT04750226) | AbbVie | 2021-02-18 |
| Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease (NCT04380142) | AbbVie | 2020-10-19 |
| Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease (NCT04379050) | AbbVie | 2020-06-08 |
| A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) (NCT03781167) | AbbVie | 2019-04-29 |
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (NCT03829657) | Theravance Biopharma | 2019-02-22 |
| A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment (NCT03374917) | AbbVie | 2018-04-18 |
| COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel (NCT03362879) | AbbVie | 2017-12-14 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease (NCT03033498) | AbbVie | 2017-05-17 |
| A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) (NCT02799381) | AbbVie | 2017-02-09 |
| Comprehensive Assessment of Neurodegeneration and Dementia (NCT03402919) | McGill University | 2016-06-01 |
| Establishing the Central and Peripheral Fatigue Indexes and VR Based Anti-fatigue Training Paradigm for Individuals With Parkinson Disease (NCT02017938) | Chang Gung University | 2014-12-10 |
| Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia (NCT02274766) | Adamas Pharmaceuticals, Inc. | 2014-10-01 |
| Open-Label Safety Study of ADS-5102 in PD Patients With LID (NCT02202551) | Adamas Pharmaceuticals, Inc. | 2014-07-01 |
| Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects (NCT02103894) | Molecular NeuroImaging | 2014-02-01 |
| Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI) (NCT01888185) | Milton S. Hershey Medical Center | 2012-12-01 |
| Intranasal Glutathione in Parkinson's Disease (NCT01398748) | Bastyr University | 2012-07-01 |
| The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics (NCT02170376) | Bial - Portela C S.A. | 2011-09-01 |
| An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites (NCT02169427) | Bial - Portela C S.A. | 2011-03-01 |
| Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics (NCT02169414) | Bial - Portela C S.A. | 2010-02-01 |
| Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin (NCT02169440) | Bial - Portela C S.A. | 2009-06-01 |
| Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (NCT02169466) | Bial - Portela C S.A. | 2009-01-01 |
| Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa (NCT02169453) | Bial - Portela C S.A. | 2008-10-01 |
| Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide (NCT02169895) | Bial - Portela C S.A. | 2008-09-01 |
| Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa (NCT02169479) | Bial - Portela C S.A. | 2008-09-01 |
| Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067 (NCT02071810) | Bial - Portela C S.A. | 2008-04-01 |
| Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide (NCT02778594) | Bial - Portela C S.A. | 2005-09-01 |
| Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients (NCT02834507) | Bial - Portela C S.A. | 2005-03-01 |